322 related articles for article (PubMed ID: 2196168)
21. Pharmacodynamics and pharmacokinetics of pinacidil after a single dose of a new slow release tablet in healthy volunteers.
Bareggi SR; Gambaro V; Valenti M; Benvenuti C
Arzneimittelforschung; 1998 Jul; 48(7):730-3. PubMed ID: 9706373
[TBL] [Abstract][Full Text] [Related]
22. Pinacidil, a new vasodilator, in the treatment of mild to moderate essential hypertension.
D'Arcy V; Laher M; McCoy D; Sullivan P; Walsh CH; Hickey MP
Eur J Clin Pharmacol; 1985; 28(3):347-9. PubMed ID: 4007040
[TBL] [Abstract][Full Text] [Related]
23. Vasodilator monotherapy in the treatment of hypertension: comparative efficacy and safety of pinacidil, a potassium channel opener, and prazosin.
Goldberg MR; Sushak CS; Rockhold FW; Thompson WL
Clin Pharmacol Ther; 1988 Jul; 44(1):78-92. PubMed ID: 3292105
[TBL] [Abstract][Full Text] [Related]
24. Comparative effects of pinacidil and prazosin on blood pressure, weight, plasma volume, the renin-angiotensin-aldosterone system, and the renal kallikrein-kinin system in patients with essential hypertension.
Solomon RJ; Weinberg MS
J Clin Hypertens; 1987 Dec; 3(4):589-95. PubMed ID: 3330989
[TBL] [Abstract][Full Text] [Related]
25. Effect of pinacidil on blood pressure, plasma catecholamines and plasma renin activity in essential hypertension.
Muiesan G; Fariello R; Muiesan ML; Christensen OE
Eur J Clin Pharmacol; 1985; 28(5):495-9. PubMed ID: 3899669
[TBL] [Abstract][Full Text] [Related]
26. The effects of long-acting pinacidil on intra-arterial blood pressure.
Caruana MP; Al-Khawaja I; Royston P; Raftery EB
Br J Clin Pharmacol; 1985 Aug; 20(2):140-3. PubMed ID: 4041331
[TBL] [Abstract][Full Text] [Related]
27. Lacidipine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of hypertension.
Lee CR; Bryson HM
Drugs; 1994 Aug; 48(2):274-96. PubMed ID: 7527328
[TBL] [Abstract][Full Text] [Related]
28. Pinacidil monotherapy for hypertension.
Ward JW
Br J Clin Pharmacol; 1984 Aug; 18(2):223-5. PubMed ID: 6487460
[TBL] [Abstract][Full Text] [Related]
29. Acute hemodynamic effects of pinacidil and hydralazine in essential hypertension.
Carlsen JE; Kardel T; Lund JO; McNair A; Trap-Jensen J
Clin Pharmacol Ther; 1985 Mar; 37(3):253-9. PubMed ID: 2857601
[TBL] [Abstract][Full Text] [Related]
30. Felodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension.
Saltiel E; Ellrodt AG; Monk JP; Langley MS
Drugs; 1988 Oct; 36(4):387-428. PubMed ID: 3069435
[TBL] [Abstract][Full Text] [Related]
31. Pinacidil, a new vasodilator: pharmacokinetics and pharmacodynamics of a new retarded release tablet in essential hypertension.
Carlsen JE; Kardel T; Jensen HA; Tangø M; Trap-Jensen J
Eur J Clin Pharmacol; 1983; 25(4):557-61. PubMed ID: 6653652
[TBL] [Abstract][Full Text] [Related]
32. Angiotensin-converting enzyme inhibitors in hypertension: a review.
Salvetti A; Pedrinelli R; Arzilli F; Abdel-Haq B; Magagna A; Lucarini A; Graziadei L; Nuccorini A; Taddei S
Int J Clin Pharmacol Res; 1985; 5(6):429-38. PubMed ID: 3005182
[TBL] [Abstract][Full Text] [Related]
33. Verapamil. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension.
McTavish D; Sorkin EM
Drugs; 1989 Jul; 38(1):19-76. PubMed ID: 2670511
[TBL] [Abstract][Full Text] [Related]
34. Comparison of antihypertensive, renal hemodynamic, and humoral effects of pinacidil and hydralazine monotherapy.
Abraham PA; Halstenson CE; Matzke GR; Keane WF
J Clin Hypertens; 1987 Dec; 3(4):439-51. PubMed ID: 3330986
[TBL] [Abstract][Full Text] [Related]
35. A double-blind, randomized, controlled trial comparing pinacidil to hydralazine in essential hypertension.
Byyny RL; Nies AS; LoVerde ME; Mitchell WD
Clin Pharmacol Ther; 1987 Jul; 42(1):50-7. PubMed ID: 3297468
[TBL] [Abstract][Full Text] [Related]
36. Angiotensin II receptor antagonists role in arterial hypertension.
Hernández-Hernández R; Sosa-Canache B; Velasco M; Armas-Hernández MJ; Armas-Padilla MC; Cammarata R
J Hum Hypertens; 2002 Mar; 16 Suppl 1():S93-9. PubMed ID: 11986904
[TBL] [Abstract][Full Text] [Related]
37. The place of isradipine in the treatment of hypertension.
Man in't Veld AJ
Am J Hypertens; 1991 Feb; 4(2 Pt 2):96S-102S. PubMed ID: 1827026
[TBL] [Abstract][Full Text] [Related]
38. Systemic and coronary hemodynamic effects of pinacidil, a new antihypertensive agent, in awake dogs: comparison with hydralazine.
Kawashima S; Liang CS
J Pharmacol Exp Ther; 1985 Feb; 232(2):369-75. PubMed ID: 3968638
[TBL] [Abstract][Full Text] [Related]
39. Manidipine: a review of its use in hypertension.
Cheer SM; McClellan K
Drugs; 2001; 61(12):1777-99. PubMed ID: 11693466
[TBL] [Abstract][Full Text] [Related]
40. Pinacidil-induced vascular relaxation: comparison to other vasodilators and to classical mechanisms of vasodilation.
Cohen ML; Kurz KD
J Cardiovasc Pharmacol; 1988; 12 Suppl 2():S5-9. PubMed ID: 2466179
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
